NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Elephas Biosciences

Elephas Biosciences

Private
Madison, WisconsinHealthcare & Life Scienceshttps://elephas.com/

Last Round

Series B

Extension

Nov 6, 2025

Total Funding Raised

$212.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Elephas Biosciences is a biotechnology company that develops a precision oncology platform utilizing artificial intelligence and advanced 3D imaging to test live patient tumor biopsies against potential therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Usage-Based SaaS, Hardware Sales

AI Layer

Application

Keywords

ex vivo diagnosticstumor profilingoncology drug developmentlive tumor tissuedrug response testingprecision medicineorgan-on-a-chipclinical trial de-riskingtherapeutic efficacybiotech servicesdrug discovery platformcancer research toolspreclinical testinglab-on-a-chip

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Elephas Biosciences Comps

Public and private peers based on sector, stage, and business model.

Elephas Biosciences comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Elephas Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionNov 6, 2025
Series CJan 23, 2024
Series BSep 6, 2022
Series AOct 14, 2021
Series ASep 15, 2021
Seed
Apr 1, 2020

Key People

Founding team and executive leadership

Maneesh Arora

Chief Executive Officer

Executive Team

Terry Brady

Chief Financial Officer

Executive Team

Elephas Biosciences Investors

Notable investors and investment history

Elephas Biosciences investors
InvestorRounds
ARCH Venture PartnersSeries B Extension, Series C, Series B
WARF VenturesSeries A, Series C, Series B
State of Wisconsin Investment BoardSeries B Extension, Series C
Northpond VenturesSeries B Extension, Series C, Series B
Moore Strategic VenturesSeries C, Series B
Venture Investors Health FundSeries B Extension, Series C
ARCH Venture PartnersSeries B Extension, Series C, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2026

    Partnering with Mithrl to accelerate research using their AI platform.

  • Feb 1, 2026

    Partnering with the University of Louisville on cancer therapy research.

Elephas Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Elephas Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Elephas Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersMadison, Wisconsin
Employee Range163
Year Founded2020
Last FundingNov 6, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.